Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.